• Otsuka Pharmaceutical Co. Ltd., of Tokyo, and H. Lundbeck A/S, of Copenhagen, Denmark, said that Abilify Maintena (ariprazole), an extended-release (once-monthly) injectable suspension for schizophrenia will become available on the U.S. market on March 18, following its approval by the FDA on Feb. 28.